Publication Name	World Journal of Hepatology
Manuscript ID	31403
Country	Türkiye

Received	2016-11-15 09:24
Peer-Review Started
To Make the First Decision	2016-11-18 14:06
Return for Revision	2016-11-18 15:13
Revised	2016-11-22 19:52
Second Decision	2016-12-02 08:50
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-12-09 18:08
Articles in Press	2016-12-09 18:08
Publication Fee Transferred
Edit the Manuscript by Language Editor	2016-12-20 06:03
Typeset the Manuscript	2017-02-14 08:09
Publish the Manuscript Online	2017-02-17 08:32

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Review
Article Title	Adverse effects of oral antiviral therapy in chronic hepatitis B
Manuscript Source	Invited Manuscript
All Author List	Bircan Kayaaslan and Rahmet Guner
Funding Agency and Grant Number
Corresponding Author	Bircan Kayaaslan, MD, Department of Infectious Disease and Clinical Microbiology, Yildirim Beyazit University Faculty of Medicine, Ataturk Education and Research Hospital, Bilkent Street no: 1, 06800 Ankara, Turkey. drbican@gmail.com
Key Words	Nucleoside/nucleotide analogues; Adverse events; Lamivudine; Chronic hepatitis B; Side effects; Safety; Telbivudine; Hepatitis B infection; Adefovir; Entecavir; Adverse effects; Tenofovir; Hepatitis B virus
Core Tip	Extrahepatic effects of nucleotide analogues (i.e., myopathy, nephropathy, bone disorders) are more commonly indicated in current reports. Some of these adverse events can be attributed to their effect of causing mitochondrial dysfunction. These adverse events are named as “class effects” and mostly associated with lamivudine and telbivudine treatment. Adefovir is a well-known nephrotoxic agent. Nephrotoxic and bone density loss effects of tenofovir in patients with chronic hepatitis B (CHB) are not as clear as in those with human immunodeficiency virus infection. Serum creatinine, phosphorus and creatine kinase levels should be monitored. Safety profile is a major issue that should not be ignored in the treatment of CHB.
Publish Date	2017-02-17 08:32
Citation	Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241
URL	http://www.wjgnet.com/1948-5182/full/v9/i5/227.htm
DOI	http://dx.doi.org/10.4254/wjh.v9.i5.227

Full Article (PDF)	WJH-9-227.pdf
Full Article (Word)	WJH-9-227.doc
Manuscript File	31403-Review.docx
Answering Reviewers	31403-Answering reviewers.pdf
Audio Core Tip	31403-Audio core tip.3gp
Conflict-of-Interest Disclosure Form	31403-Conflict-of-interest statement.pdf
Copyright License Agreement	31403-Copyright assignment.pdf
Peer-review Report	31403-Peer-review(s).pdf
Scientific Misconduct Check	31403-Scientific misconduct check.pdf
Scientific Editor Work List	31403-Scientific editor work list.pdf